Genovis AB (publ.) (GENO) Stock Overview
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GENO from our risk checks.
GENO Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 16.98 |
| 52 Week High | SEK 29.90 |
| 52 Week Low | SEK 17.10 |
| Beta | 2.12 |
| 1 Month Change | -21.75% |
| 3 Month Change | -16.35% |
| 1 Year Change | -41.55% |
| 3 Year Change | -73.84% |
| 5 Year Change | -59.57% |
| Change since IPO | -84.13% |
Recent News & Updates
Genovis AB (publ.) Just Recorded A 14% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 15
Genovis AB (publ.)'s (STO:GENO) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 15Results: Genovis AB (publ.) Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 12Recent updates
Genovis AB (publ.) Just Recorded A 14% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 15Genovis AB (publ.)'s (STO:GENO) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 15Results: Genovis AB (publ.) Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 12Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Sep 03Genovis AB (publ.) (STO:GENO) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 15Calculating The Intrinsic Value Of Genovis AB (publ.) (STO:GENO)
Jul 08Weak Statutory Earnings May Not Tell The Whole Story For Genovis AB (publ.) (STO:GENO)
May 05Genovis AB (publ.)'s (STO:GENO) 25% Share Price Surge Not Quite Adding Up
Apr 27An Intrinsic Calculation For Genovis AB (publ.) (STO:GENO) Suggests It's 32% Undervalued
Mar 27Investors Appear Satisfied With Genovis AB (publ.)'s (STO:GENO) Prospects
Mar 07Is It Time To Consider Buying Genovis AB (publ.) (STO:GENO)?
Feb 01Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 19Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings
Aug 28Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts
Aug 23The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts
Aug 21Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Aug 12Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors
May 31This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate
May 09Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22Shareholder Returns
| GENO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -13.5% | -7.2% | -1.7% |
| 1Y | -41.5% | -18.9% | 1.7% |
Return vs Industry: GENO underperformed the Swedish Life Sciences industry which returned -18.9% over the past year.
Return vs Market: GENO underperformed the Swedish Market which returned 1.7% over the past year.
Price Volatility
| GENO volatility | |
|---|---|
| GENO Average Weekly Movement | 5.5% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: GENO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: GENO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 36 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues.
Genovis AB (publ.) Fundamentals Summary
| GENO fundamental statistics | |
|---|---|
| Market cap | SEK 1.16b |
| Earnings (TTM) | SEK 23.50m |
| Revenue (TTM) | SEK 129.65m |
Is GENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENO income statement (TTM) | |
|---|---|
| Revenue | SEK 129.65m |
| Cost of Revenue | SEK 13.80m |
| Gross Profit | SEK 115.85m |
| Other Expenses | SEK 92.35m |
| Earnings | SEK 23.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 89.36% |
| Net Profit Margin | 18.12% |
| Debt/Equity Ratio | 0% |
How did GENO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 18:45 |
| End of Day Share Price | 2026/02/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genovis AB (publ.) is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Larsson | Danske Bank |
| Ludvig Lundgren | Nordea Markets |
| Filip Einarsson | Redeye |